Company intelligence / Profile preview

Cullgen Inc.

San Diego, California, United Statescullgen.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Currently in Phase 1 dosing of CG001419, an oral pan-TRK protein degrader for acute and chronic pain. The company has also received Chinese NMPA allowance for an investigational new drug application for CG009301, a selective GSPT1 degrader.

Therapeutic areas: OncologyImmunologyNeurology
Modalities: Small moleculestargeted protein degradersdegrader-antibody conjugates (DACs)
Industry: Biotech

Drug pipeline

12 assets

CG001419

11 more assets in the full pipeline.

Request access →

Partnerships

Astellas PharmaAstraZeneca-CICC Venture Capital PartnershipPulmatrix (proposed merger)

Beyond the preview

Go deeper on Cullgen Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cullgen Inc..

Explore the full profile